Kura and Profound Q4 Results: Pivotal 2026 for Precision Medicine

The fourth-quarter 2025 earnings reports from Kura Oncology and Profound Medical offer a compelling look at the current state of specialized healthcare, where clinical promise and operational efficiency are being weighed against the friction of commercial scaling. For Kura Oncology, the quarter was defined by the initial market entry of KOMZIFTI (ziftomenib), its lead menin inhibitor for acute myeloid leukemia (AML). Despite a headline revenue miss—reporting $17.34 million against much higher expectations—the company is positioning itself for a massive long-term play. Management has identified a $7 billion total addressable market in AML as they advance combination strategies that could move KOMZIFTI into earlier lines of therapy.

The divergence between Kura’s financial results and its strategic outlook is typical for high-growth biotech. The GAAP EPS loss of $0.92, which missed analyst estimates by $0.18, reflects the heavy investment required to support a global launch and ongoing Phase 3 trials. However, the qualitative data from the call suggests that payers are increasingly viewing KOMZIFTI as a preferred treatment option in the menin inhibitor class. This is a critical distinction as Kura competes directly with Syndax Pharmaceuticals. The company’s ability to secure favorable formulary placement early in the launch cycle will be the primary driver of stock performance in the first half of 2026.

“

The GAAP EPS loss of $0.92, which missed analyst estimates by $0.18, reflects the heavy investment required to support a global launch and ongoing Phase 3 trials.

The competitive landscape for menin inhibitors is intensifying, with Syndax Pharmaceuticals representing a formidable rival. Kura’s strategic advantage may lie in its combination therapy approach, which aims to integrate ziftomenib into frontline treatments rather than just relapsed or refractory cases. This pivot is essential for capturing a larger share of the $7 billion addressable market. Analysts are closely watching how Kura manages its cash runway as it scales these trials, as the $0.92 EPS loss indicates a high burn rate that must eventually be offset by a steepening revenue curve.

In contrast, Profound Medical’s Q4 results showcased a different kind of financial resilience. The medical device firm delivered a significant surprise on the bottom line, reporting a GAAP EPS of $0.27, which beat consensus estimates by a wide margin of $0.55. This profitability, even if bolstered by one-time items or aggressive cost management, signals a maturing operational profile. However, like Kura, Profound faced challenges on the top line, with revenue of $6 million missing targets by $1.72 million. This suggests that while the company is managing its capital efficiently, the adoption of its TULSA-PRO system—an incision-less, MRI-guided prostate ablation technology—continues to face the typical 'S-curve' adoption challenges seen in high-capital medical equipment.